๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2026-07-23

Evaluating Microarray Pharmacogenetic Testing in Cancer Patients (NCT06489041)

Evaluating the Use of Microarray Pharmacogenetic Testing in Patients With Cancer

๐Ÿ”ต Active, Not Recruiting Observational / Diagnostic ๐Ÿ“‹ Clinical Research Protocol Sponsor: Wake Forest University Health Sciences

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.

Who can join: Review the eligibility criteria below.

Location: Atrium Health Levine Cancer โ€” Charlotte, North Carolina

Age range: 18 Years

๐Ÿงช Interventions in This Study

  • Pharmacogenomic Testing with the "Global Diversity Array with Enhanced PGx" (GENETIC)

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (1 Sites)

  • Atrium Health Levine Cancer โ€” Charlotte, North Carolina

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Cancer clinical trials

๐Ÿ’ก How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
๐Ÿ›๏ธ View Official NIH Record โ†—